Could you be 1 of the estimated 3300 patients in the US with the gene causing SORD Deficiency? You may have been diagnosed with CMT2, or distal hereditary motor neuropathy (dHMN). Join us as we learn more about SORD Deficiency and an investigational NEW Treatment with Shoshana Shendelman, Founder and CEO of Applied Therapeutics.
The Future of CMT Research
Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or research.
0 Comments